NCT00615966 - Phase 2 Study of the Safety of Diannexin in Kidney Transplant Recipients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 29, 2008

Primary Completion Date

January 31, 2009

Study Completion Date

February 28, 2010

Conditions

Kidney Transplantation

Interventions

DRUG

Diannexin

single dose, 200 µg/kg IV

DRUG

Placebo

Single dose, IV

DRUG

Diannexin

Single dose, 400 µg/kg IV

Trial Locations (5)

New York-Presbyterian Hospital/Weill Cornell Medical Center, New York

University of Maryland, Baltimore

Wake Forest University Baptist Medical Center, Winston-Salem

University of Wisconsin Medical School, Dept of Surgery, Madison

St Barnabas Medical Center, Livingston